Does OLAPARIB Cause Disease progression? 423 Reports in FDA Database
Prostate Health & Male Vitality — Naturally
ProstaVive: better flow, better sleep, better energy. 180-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 423 reports of Disease progression have been filed in association with OLAPARIB (Lynparza). This represents 2.3% of all adverse event reports for OLAPARIB.
423
Reports of Disease progression with OLAPARIB
2.3%
of all OLAPARIB reports
56
Deaths
37
Hospitalizations
How Dangerous Is Disease progression From OLAPARIB?
Of the 423 reports, 56 (13.2%) resulted in death, 37 (8.7%) required hospitalization, and 5 (1.2%) were considered life-threatening.
Is Disease progression Listed in the Official Label?
Yes, Disease progression is listed as a known adverse reaction in the official FDA drug label for OLAPARIB.
What Other Side Effects Does OLAPARIB Cause?
Death (4,378)
Malignant neoplasm progression (1,862)
Nausea (1,582)
Anaemia (1,455)
Fatigue (1,437)
Off label use (777)
Vomiting (642)
Drug ineffective (563)
Diarrhoea (514)
Asthenia (491)
What Other Drugs Cause Disease progression?
RITUXIMAB (7,282)
CYCLOPHOSPHAMIDE (7,100)
DOXORUBICIN (6,165)
VINCRISTINE (5,252)
PREDNISONE (5,096)
BEVACIZUMAB (4,653)
DEXAMETHASONE (4,545)
CARBOPLATIN (4,538)
CAPECITABINE (3,808)
ETOPOSIDE (3,776)
Which OLAPARIB Alternatives Have Lower Disease progression Risk?
OLAPARIB vs OLARATUMAB
OLAPARIB vs OLECLUMAB
OLAPARIB vs OLIVE OIL\SOYBEAN OIL
OLAPARIB vs OLMESARTAN
OLAPARIB vs OLMESARTAN MEDOXOMIL